Mode
Text Size
Log in / Sign up
N/A N=155 Treatment

BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease

Peripheral Artery Disease · Peripheral Vascular Disease · Arterial Occlusive Disease

Enrolled (actual)
155
Serious AEs
38.7%
Results posted
Oct 2020
Primary outcome: Primary: Number of Participants With Device and/or Procedure-Related Death or Myocardial Infarction (MI) Through 30 Days, or Any Target Lesion Revascularization (TLR), Target Limb(s) Major Amputation, or Restenosis Through 9-Months Post Index Procedure. — 16 Participants — p=<0.0325

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Percutaneous transluminal angioplasty (PTA) (Procedure); LIFESTREAM™ covered stent (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
C. R. Bard
Primary completion
Dec 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Device and/or Procedure-Related Death or Myocardial Infarction (MI) Through 30 Days, or Any Target Lesion Revascularization (TLR), Target Limb(s) Major Amputation, or Restenosis Through 9-Months Post Index Procedure.
16 <0.0325 sig
SECONDARY
Number of Participants With Major Adverse Events (MAEs) Through 9-Months Post Index Procedure.
7
SECONDARY
Number of Lesions With Acute Lesion Success
188
SECONDARY
Number of Participants With Acute Procedure Success
148
SECONDARY
Number of Devices With Acute Technical Success at Index Procedure
226
SECONDARY
Number of Participants With Target Lesion Revascularization (TLR) at 6, 9, 12, 24, and 36 Months Post Index Procedure
3; 5; 7; 19; 23
SECONDARY
Number of Participants With Target Vessel Revascularization (TVR) Event at 6, 9, 12, 24, and 36 Months Post Index Procedure.
3; 5; 7; 19; 23
SECONDARY
Number of Participants With Sustained Clinical Success at 30-Days and 9, 12, 24, and 36 Months Post Index Procedure
133; 124; 124; 106; 98
SECONDARY
Number of Participants With Primary Patency at 9, 12, 24, and 36 Months Post Index Procedure
118; 110; 92; 72
SECONDARY
Number of Participants With Assisted Primary Patency at 9, 12, 24, and 36 Months Post Index Procedure
119; 112; 98; 78
SECONDARY
Number of Participants With Secondary Patency at 9, 12, 24, and 36 Months Post Index Procedure.
121; 112; 100; 79
SECONDARY
Change in Walking Impairment Questionnaire (WIQ) Scores at 30 Days, 9, 12, 24, and 36-Months Post Index Procedure Compared to Baseline.
31.45; 32.10; 32.81; 31.34; 32.52

Summary

Collect confirmatory evidence of the safety and effectiveness of the Balloon LIFESTREAM™ Stent Graft for the treatment of stenoses and occlusion in the iliac arteries.

Eligibility Criteria

CLINICAL INCLUSION CRITERIA:

  • The subject provides written informed consent using an Informed Consent Form approved by the Ethics Committee/ Institutional Review Board for the site.
  • Subject agrees to comply with the protocol-mandated follow-up procedures and visits.
  • Subject is a male or non-pregnant female ≥ 21 years old with an expected lifespan sufficient to allow for completion of all study procedures.
  • Subject has intermittent claudication (Rutherford Category 2-3) or ischemic rest pain (Rutherford Category 4).
  • Subject is able and willing to comply with any required medication regimen.

ANGIOGRAPHIC INCLUSION CRITERIA:

  • Subject has evidence of single, bilateral, or multiple de novo and/or restenotic (non-stented) lesion in the native common and/or external iliac artery that is ≥ 50% stenosed (including total occlusions).
  • The target lesion can be successfully crossed with a guide wire and pre-dilated with an appropriately sized PTA balloon.
  • The reference vessel diameter is between 4.5 mm -12.0 mm in diameter.
  • The target lesion is ≤ 100 mm in combined length (per side).
  • The subject has angiographic evidence of a patent (< 50% stenosis) profunda and/or superficial femoral artery (SFA) in the target limb.

CLINICAL EXCLUSION CRITERIA:

  • The subject is unable or unwilling to provide written informed consent or to conform to the study protocol follow-up procedures and visits.
  • The subject is or plans to become pregnant during the study.
  • The subject is asymptomatic, has mild claudication or critical limb ischemia with tissue loss described as Rutherford Category 0, 1, 5 or 6.
  • The subject has a vascular graft previously implanted in the native iliac vessel.
  • The subject suffered a hemorrhagic stroke or transient ischemic attack (TIA) within 3 months prior to the index procedure.
  • The subject has a known uncorrectable bleeding diathesis or active coagulopathy.
  • The subject has a serum creatinine ≥ 2.5 mg/dl or is on dialysis.
  • The subject has a known allergy or sensitivity to stainless steel (i.e., Nickel), ePTFE, or has intolerance to the antiplatelet, anticoagulant or thrombolytic medications required per the protocol.
  • The subject has a known allergy or sensitivity to contrast media, which cannot be adequately pre-medicated.
  • The subject had a prior vascular intervention within 30 days before or planned for within 30 days after the index procedure.
  • The subject has another medical condition, which may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.
  • The subject is currently participating in an investigational drug, biologic, or another device study.

ANGIOGRAPHIC EXCLUSION CRITERIA:

  • The subject has extensive peripheral vascular disease, which in the opinion of the Investigator, would preclude safe insertion of an introducer sheath. The ipsilateral common femoral artery should be patent (< 50% stenosis).
  • The target lesion requires treatment other than angioplasty to facilitate subject device delivery.
  • The subject has severe calcification of the target lesion, preventing inflation of PTA balloon.
  • The target lesion has been previously treated with a stent (bare or covered).
  • The subject has angiographic evidence of acute thrombus at the target lesion.
  • The target lesion involves the origin of the internal iliac artery such that successful treatment of the lesion would require the subject device to cross/occlude the side branch.
  • The target lesion located in the distal external iliac artery such that successful treatment of the lesion would require the subject device to cross/occlude side branches or be exposed to compressive forces associated with the close proximity to the common femoral artery.
  • The subject has an abdominal aortic aneurysm (AAA) contiguous to the iliac artery target lesion.
  • The subject has a pre-existing target il
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02228564). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search